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Natural killer (NK) cells
• A class of lymphocytes
• Part of the innate immune response
(do not require antibodies to function)
• In charge of “immunosurveillance”
• NK cells patrol the body for infected
cells or foreign cells
• Kill cells that are foreign or are
infected using cytotoxic granules
• Granulated, non-phagocytotic cells
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NK recognition of normal cells
• All nucleated body cells have a surface
major histocompatibility complex class I
(MHC I) on their cell surface
• When on a normal human cell, MHC I
proteins present either self antigen or
the antigen of a foreign agent (e.g.,
virus)
• When the self-antigen is detected by the
NK cell, the NK is prohibited from
attacking that cell through inhibition
• This mechanism is known as selftolerance

NK cells: 3 different functions
• Regulatory NK cells stimulate
an immune response
• Cytotoxic NK cells prioritize
killing unwanted cells
• Memory NK cells can be tied to
the specific immune response
through antibodies
• Takeaway: NK cells, on top of
killing cells, can trigger a
further immune response

Combination of inhibitory and activating
signals on target cells
• NK cells act upon a balance of
inhibitory and activating signals
• MHC Class I
• Self-antigen → inhibition
• Foreign antigen → activation
• Lack of MHC Class I on target cell →
activation (may be cancer, infected
cell, or bacteria)

• Surface Proteins on Target Cell
• Certain proteins on the target cell’s
membrane activate or inhibit the
cytotoxicity of NK cells

NK cell dysfunction
• Dysfunction
• Increased inhibition/
decreased activation→
weaker immune response
• Increased
activation/decreased
inhibition→ autoimmune
disease
• Balanced inhibitory and
activating signals → normal
functioning

NK activation and inhibition via cell surface
• NK cells can be activated or
inhibited via their own cell
surface
• Molecules and receptors that
interact with/at the cell
surface of the NK cells are
known as immune
checkpoint
molecules/receptors
• Improper regulation of these
immune checkpoints can also
lead to NK cell dysfunction

Potential application of NK cells: cancer
• Natural killer cells on their own kill cancer
• Providing NK cells means reduced cancer
• In patients on chemotherapy, their immune response is suppressed even
though the cancer cell are being killed
• To reinvigorate the immune system (as well as initiative anti-tumor
response), NK cells can be added/proliferated within the body
• Autologous transplant
• Allogeneic transplant

• However, regulating immune checkpoints can also lead to a variable NK
response
• Clinical trials are already in the running to investigate the effects of NK cells
against cancer

Regulating immune checkpoint molecules
• Many immune checkpoint molecules are
inhibitory in nature (they prevent the
cytotoxic effects of NK cells against
unwanted cells)
• If inhibitory immune checkpoint molecules
are not controlled, there may be excess
inhibition of NK cells, leading to virus or
cancer proliferation
• Antibody immune targeting of inhibitory
immune checkpoints → lowered inhibition
of NK cells

Tumor microenvironment (TME)
• In the TME, the NK cells are altered, allowing cancer cells to escape
detection
• NK cells primary do this through inhibitory receptor proteins
• KIRs contribute to recognition of self-antigen, providing inhibitory signal for
NK activation
• PD-1 (programmed cell death protein 1) is high expressed in NK cells in the
TMEs of certain cancers

• However, decreased activation also occurs
• NKG2D is an activating receptor on NK cells
• The concentration of NKG2D ligands is lower in the TME

Immunotherapies for cancer using NK cells
• Targeting inhibitory proteins on NK cells through antibodies could serve as
an immunotherapeutic approach for cancer
• Monoclonal antibodies for immune checkpoint molecules involved in the
suppression of NK cells have been shown to treat cancer
• Recent methodologies have also been developed using the mAb-mediated
blockade of definite NK cell immune checkpoints
• Studies using immunotherapies against cancer cells have been effective
• One recent study (mentioned in the paper) found that increased activation
of NKG2D is better than targeting inhibitory receptors
• The use of NK cells may be of particular interest as many cancers are
becoming chemo-resistant

Regulatory T cell interactions
• Regulatory T cells suppress the population
expansion of NK cells
• Downregulating T cells may be an effective
method of increased NK populations
• However, downregulating T cells may mean a
lowered immune response

Adenosine interactions
• Cancer cells may elicit
adenosine generation,
converting NK cells into
dysfunctional cells through
hypoxia
• Cancer tissue have large ATP
demands
• Hypoxia convert these ATP
molecules into ADO,
suppressing the immune
response

Conclusions
• NK cells play an important role in monitoring cells within the body
• NK cells can secrete cytokines, triggering a further immune response
• NK cells can also kill unwanted cells (including cancer)
• NK cells can also provide to immunity through memory NK cells

• In the TME, NK cells are altered, leading to an imbalance of NK
activating and inhibiting signals, contributing to NK dysfunction
• Immunotherapies targeted against immune suppression have worked,
but activating methods also show promise
• Current methods for exploring NK-mediated immunotherapy for
cancer should be further investigated

Discussion Questions
• Immunology is a rapidly developing field. New cellular mechanisms
are found quite regularly. The dendritic cell, for example, was
discovered only in 1973. How does our understanding of immunity
change our world today?
• Cancer types are rapidly becoming chemo-resistant, meaning that
they are resistant to chemotherapy, the traditional treatment for
cancer. Should we switch to using NK cells to treat cancer?
• Should we rely more on combined therapeutic techniques to treat
illnesses/diseases?

Discussion Questions
• Our bodies also can develop autoimmunity thanks to the immune
system. Should we try to harness the immune system to kill unwanted
cells, or should we rely on other means to fight off
infection/illnesses?
• Cancer diagnosis and treatment can be very devastating for patients.
How can we adopt a more holistic approach to fighting cancer?
• To function optimally, NK cells require a balance of activating and
inhibitory signals. Does the complexity of our bodies serve as a
hindrance towards our health?
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